TABLE 2

Change in haemodynamics from baseline (the last documented value while still receiving phosphodiesterase-5 inhibitor) to week 24 and last-observation-carried-forward (LOCF) sensitivity analysis

ParameterNValue at week 24Change from baseline to week 24#nLOCFLOCF change from baseline
PVR dyn·s·cm–549753±379–103±29661762±367–74±277
Cardiac output L·min–1494.7±1.2+0.6±0.9614.6±1.1+0.4±0.9
Cardiac index L·min–1·m–2482.6±0.6+0.3±0.5612.6±0.5+0.2±0.5
mPAP mmHg4950±13–2.8±8.86150±14–2.2±8.0
RAP mmHg498.0±4.3–0.8±4.2617.7±4.4–0.6±3.8
SvO2 %4465.0±7.6+1.0±6.35865.4±7.0+0.7±5.5
SVR+ dyn·s·cm–5491417±398–218±444601446±388–179±415
PAWP mmHg499.0±4.1–0.7±4.2618.9±4.1–0.5±3.8
SBP mmHg53113±13–5±1661112±15–6±15
DBP mmHg5368±8–4±126168±10–5±12
Heart rate beats per min5374±12<–0.5±116177±12+2±11

Data are presented as mean±sd, unless otherwise stated. #: these data include only those patients for whom the respective variables were available at baseline and at week 24; : data missing at baseline for two patients; +: data missing at baseline for one patient. PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure; RAP: right atrial pressure; SvO2 : mixed venous oxygen saturation; SVR: systemic vascular resistance; PAWP: pulmonary artery wedge pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.